Join experts Drs Kevin Kalinsky and Heather McArthur as they discuss the latest studies guiding their decisions when treating patients with TNBC in clinic.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991253). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Pembrolizumab Plus Chemotherapy in Advanced Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35857659/
Pembrolizumab for Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32101663/
Event-free Survival With Pembrolizumab in Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35139274/
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab https://classic.clinicaltrials.gov/ct2/show/NCT05812807
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells https://pubmed.ncbi.nlm.nih.gov/34413126/
Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/33882206/
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2023-00614&r=1
Adjuvant Capecitabine for Breast Cancer After Preoperative Chemotherapy https://pubmed.ncbi.nlm.nih.gov/28564564/
A Phase Ib Trial of Pembrolizumab Plus Paclitaxel or Flat-dose Capecitabine in 1st/2nd Line Metastatic Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37344474/
Adjuvant Olaparib for Patients With BRCA1- or BRCA2-mutated Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34081848/
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer https://classic.clinicaltrials.gov/ct2/show/NCT02954874
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer (IMpassion030) https://classic.clinicaltrials.gov/ct2/show/NCT03498716
Neoadjuvant Atezolizumab in Combination With Sequential Nab-paclitaxel and Anthracycline-based Chemotherapy Versus Placebo and Chemotherapy in Patients With Early-stage Triple-negative Breast Cancer (IMpassion031): A Randomised, Double-blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/32966830/
LBA1 - Final Analysis of the Placebo-controlled Randomised Phase 3 IMpassion031 Trial Evaluating Neoadjuvant Atezolizumab (Atezo) Plus Chemotherapy (CT) Followed by Open-label Adjuvant Atezo in Patients (pts) With Early-stage Triple-negative Breast Cancer (eTNBC) https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress/final-analysis-of-the-placebo-controlled-randomised-phase-3-impassion031-trial-evaluating-neoadjuvant-atezolizumab-atezo-plus-chemotherapy-ct-f
The I-SPY Trials https://www.ispytrials.org/
BEGONIA: Phase 1b/2 Study of Durvalumab (D) Combinations in Locally Advanced/Metastatic Triple-negative Breast Cancer (TNBC)—Initial Results From Arm 1, D+Paclitaxel (P), and Arm 6, D+Trastuzumab Deruxtecan (T-DXd). https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1023